Related Experiment Video
Updated: Aug 19, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.2K
Management of systemic prostate cancer: current algorithm from castration sensitive to castration resistant setting
C D'Aniello1, C Cavaliere, C Foglia
1Division of Medical Oncology, AORN dei Colli Ospedali Monaldi-Cotugno-CTO, Naples, Italy. carla.cavaliere@hotmail.it.
European Review for Medical and Pharmacological Sciences
|December 2, 2022
Summary
Recent advances in prostate cancer knowledge have introduced new treatments and strategies for managing systemic disease. This review integrates these developments for improved medical management of castration-sensitive and castration-resistant prostate cancer.
Area of Science:
- Oncology
- Medical Science
Background:
- Growing understanding of prostate cancer's clinical, biological, and molecular aspects.
- Emergence of new treatment paradigms for systemic prostate cancer, including high-risk/high-volume versus low-risk/low-volume disease.
Approach:
- Reviewing and integrating recent advancements in prostate cancer drug development and application.
- Exploring the evolving landscape of systemic disease management and sequence therapy.
Key Points:
- New drugs and repurposed existing drugs are changing treatment settings for prostate cancer.
- Distinguishing between high-risk/high-volume and low-risk/low-volume castration-sensitive prostate cancer (CSPC) impacts treatment.
- Previously approved drugs for castration-resistant prostate cancer (CRPC) are being reconsidered, opening new therapeutic sequences.
Conclusions:
- The integration of new knowledge is crucial for optimizing medical management of systemic prostate cancer.
- Evolving treatment strategies offer new possibilities for sequence therapy in advanced prostate cancer.
